transferrin has been researched along with Hyperlipoproteinemias in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arneth, B; Bornstein, SR; Heigl, F; Hettich, R; Illigens, BM; Julius, U; Prophet, H; Ramlow, W; Schatz, U; Siegels, D; Siegert, G; Siepmann, T | 1 |
| Basista, M; Domagala, B; Dworski, R; Gryglewski, RJ; Szczeklik, A | 1 |
1 trial(s) available for transferrin and Hyperlipoproteinemias
| Article | Year |
|---|---|
Dietary supplementation with vitamin E in hyperlipoproteinemias: effects on plasma lipid peroxides, antioxidant activity, prostacyclin generation and platelet aggregability.
Topics: Adult; Animals; Blood Platelets; Ceruloplasmin; Cholesterol; Diet, Atherogenic; Epoprostenol; Female; Humans; Hyperlipoproteinemias; Lipid Peroxides; Male; Middle Aged; Oxygen; Platelet Aggregation; Rabbits; Thromboxane A2; Transferrin; Triglycerides; Vitamin E | 1985 |
1 other study(ies) available for transferrin and Hyperlipoproteinemias
| Article | Year |
|---|---|
TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
Topics: Aged; Anemia, Iron-Deficiency; Biomarkers; Blood Component Removal; Drug Administration Schedule; Female; Ferric Compounds; Ferritins; Germany; Hematinics; Humans; Hyperlipoproteinemias; Infusions, Intravenous; Iron; Lipoproteins, LDL; Male; Maltose; Middle Aged; Prospective Studies; Time Factors; Transferrin; Treatment Outcome | 2015 |